The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). (Q47613046)

4 February 2018

title

The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). (English)

1 reference

4 February 2018

0 references

1 reference

1 reference

G Hackett

1

1 reference

4 February 2018

N Cole

2

1 reference

4 February 2018

M Bhartia

3

1 reference

4 February 2018

D Kennedy

4

1 reference

4 February 2018

J Raju

5

1 reference

4 February 2018

P Wilkinson

6

1 reference

4 February 2018

A Saghir

7

1 reference

4 February 2018

Blast Study Group

8

1 reference

4 February 2018

publication date

20 December 2013

1 reference

4 February 2018

International Journal of Clinical Practice

published in

1 reference

4 February 2018

volume

68

1 reference

4 February 2018

issue

2

1 reference

4 February 2018

page(s)

203-215

1 reference

4 February 2018

Androgens, health and sexuality in women and men.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Identification of late-onset hypogonadism in middle-aged and elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Low serum testosterone and mortality in male veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Low serum testosterone and estradiol predict mortality in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Low serum testosterone and increased mortality in men with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Management of type 2 diabetes: summary of updated NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Onset of effects of testosterone treatment and time span until maximum effects are achieved

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12235

21 January 2018

Identifiers

DOI

10.1111/IJCP.12235

1 reference

4 February 2018

PubMed ID

24355040

1 reference

4 February 2018